|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mangolini A, Ferracin M, Zanzi MV,
Saccenti E, Ebnaof SO, Poma VV, Sanz JM, Passaro A, Pedriali M,
Frassoldati A, et al: Diagnostic and prognostic microRNAs in the
serum of breast cancer patients measured by droplet digital PCR.
Biomark Res. 3:122015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar :
|
|
5
|
Beckmann MW, Niederacher D, Schnürch HG,
Gusterson BA and Bender HG: Multistep carcinogenesis of breast
cancer and tumour heterogeneity. J Mol Med (Berl). 75:429–439.
1997. View Article : Google Scholar
|
|
6
|
Nakamura S, Yagata H, Ohno S, Yamaguchi H,
Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K and Suzuki E:
Multi-center study evaluating circulating tumor cells as a
surrogate for response to treatment and overall survival in
metastatic breast cancer. Breast Cancer. 17:199–204. 2010.
View Article : Google Scholar
|
|
7
|
Gong Y, He T, Yang L, Yang G, Chen Y and
Zhang X: The role of miR-100 in regulating apoptosis of breast
cancer cells. Sci Rep. 5:116502015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mar-Aguilar F, Luna-Aguirre CM,
Moreno-Rocha JC, Araiza-Chávez J, Trevino V, Rodríguez-Padilla C
and Reséndez-Pérez D: Differential expression of miR-21, miR-125b
and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol.
9:53–59. 2013. View Article : Google Scholar
|
|
9
|
Hu Y, Zhu Q and Tang L: MiR-99a antitumor
activity in human breast cancer cells through targeting of mTOR
expression. PLoS One. 9:e920992014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu
C, Li J, Wang X and Song L: Unregulated miR-96 induces cell
proliferation in human breast cancer by downregulating
transcriptional factor FOXO3a. PLoS One. 5:e157972010. View Article : Google Scholar
|
|
11
|
Lee JC, Gundara JS, Glover A, Serpell J
and Sidhu SB: MicroRNA expression profiles in the management of
papillary thyroid cancer. Oncologist. 19:1141–1147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96(Suppl): R40–R44. 2007.PubMed/NCBI
|
|
13
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Abdel-Mageed AB, Mondal D and Kandil
E: MicroRNA expression profiles in differentiated thyroid cancer, a
review. Int J Clin Exp Med. 6:74–80. 2013.
|
|
15
|
Xia M, Li H, Wang JJ, Zeng HJ and Wang SH:
MiR-99a suppress proliferation, migration and invasion through
regulating insulin-like growth factor 1 receptor in breast cancer.
Eur Rev Med Pharmacol Sci. 20:1755–1763. 2016.PubMed/NCBI
|
|
16
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016.PubMed/NCBI
|
|
17
|
Chen X, Bo L, Lu W, Zhou G and Chen Q:
MicroRNA-148b targets Rho-associated protein kinase 1 to inhibit
cell proliferation, migration and invasion in hepatocellular
carcinoma. Mol Med Rep. 13:477–482. 2016.
|
|
18
|
Marini F, Luzi E and Brandi ML: MicroRNA
role in thyroid cancer development. J Thyroid Res. 2011:4071232011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Abedi N, Mohammadi-Yeganeh S, Koochaki A,
Karami F and Paryan M: miR-141 as potential suppressor of β-catenin
in breast cancer. Tumour Biol. 36:9895–9901. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and
MiR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath
N, Orringer MB, Chang AC, Beer DG and Chen G: A MicroRNA cluster at
14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res.
20:3107–3117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harafuji N, Schneiderat P, Walter MC and
Chen YW: miR-411 is up-regulated in FSHD myoblasts and suppresses
myogenic factors. Orphanet J Rare Dis. 8:552013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yi B, Piazza GA, Su X and Xi Y: MicroRNA
and cancer chemoprevention. Cancer Prev Res (Phila). 6:401–409.
2013. View Article : Google Scholar
|
|
25
|
Zhang JX, Song W, Chen ZH, Wei JH, Liao
YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, et al: Prognostic and
predictive value of a microRNA signature in stage II colon cancer:
A microRNA expression analysis. Lancet Oncol. 14:1295–1306. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heinzelmann J, Unrein A, Wickmann U,
Baumgart S, Stapf M, Szendroi A, Grimm MO, Gajda MR, Wunderlich H
and Junker K: MicroRNAs with prognostic potential for metastasis in
clear cell renal cell carcinoma: A comparison of primary tumors and
distant metastases. Ann Surg Oncol. 21:1046–1054. 2014. View Article : Google Scholar
|
|
27
|
Xia K, Zhang Y, Cao S, Wu Y, Guo W, Yuan W
and Zhang S: miR-411 regulated ITCH expression and promoted cell
proliferation in human hepatocellular carcinoma cells. Biomed
Pharmacother. 70:158–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dynan WS and Tjian R: The
promoter-specific transcription factor Sp1 binds to upstream
sequences in the SV40 early promoter. Cell. 35:79–87. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kadonaga JT, Courey AJ, Ladika J and Tjian
R: Distinct regions of Sp1 modulate DNA binding and transcriptional
activation. Science. 242:1566–1570. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yue L, Li L, Liu F, Hu N, Zhang W, Bai X,
Li Y, Zhang Y, Fu L, Zhang X and Ye L: The oncoprotein HBXIP
activates transcriptional coregulatory protein LMO4 via Sp1 to
promote proliferation of breast cancer cells. Carcinogenesis.
34:927–935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
32
|
Yin P, Zhao C, Li Z, Mei C, Yao W, Liu Y,
Li N, Qi J, Wang L, Shi Y, et al: Sp1 is involved in regulation of
cystathionine gamma-lyase gene expression and biological function
by PI3K/Akt pathway in human hepatocellular carcinoma cell lines.
Cell Signal. 24:1229–1240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bonofiglio D, Qi H, Gabriele S, Catalano
S, Aquila S, Belmonte M and Ando S: Peroxisome
proliferator-activated receptor gamma inhibits follicular and
anaplastic thyroid carcinoma cells growth by upregulating
p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer.
15:545–557. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pathi S, Jutooru I, Chadalapaka G, Nair V,
Lee SO and Safe S: Aspirin inhibits colon cancer cell and tumor
growth and downregulates specificity protein (Sp) transcription
factors. PLoS One. 7:e482082012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang C and Xie K: Crosstalk of Sp1 and
Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth
Factor Rev. 23:25–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang YT, Chuang JY, Shen MR, Yang WB,
Chang WC and Hung JJ: Sumoylation of specificity protein 1 augments
its degradation by changing the localization and increasing the
specificity protein 1 proteolytic process. J Mol Biol. 380:869–885.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and krüppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li L, He S, Sun JM and Davie JR: Gene
regulation by Sp1 and Sp3. Biochem Cell Biol. 82:460–471. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang L, Guan X, Zhang J, Jia Z, Wei D, Li
Q, Yao J and Xie K: Targeted inhibition of Sp1-mediated
transcription for antiangiogenic therapy of metastatic human
gastric cancer in orthotopic nude mouse models. Int J Oncol.
33:161–167. 2008.PubMed/NCBI
|
|
41
|
Zhang J, Zhu ZG, Ji J, Yuan F, Yu YY, Liu
BY and Lin YZ: Transcription factor Sp1 expression in gastric
cancer and its relationship to long-term prognosis. World J
Gastroenterol. 11:2213–2217. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wright C, Angus B, Napier J, Wetherall M,
Udagawa Y, Sainsbury JR, Johnston S, Carpenter F and Horne CH:
Prognostic factors in breast cancer: Immunohistochemical staining
for SP1 and NCRC 11 related to survival, tumour epidermal growth
factor receptor and oestrogen receptor status. J Pathol.
153:325–331. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cao L, Xie B, Yang X, Liang H, Jiang X,
Zhang D, Xue P, Chen D and Shao Z: MiR-324-5p suppresses
hepatocellular carcinoma cell invasion by counteracting ECM
degradation through post-transcriptionally downregulating ETS1 and
SP1. PLoS One. 10:e01330742015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo MM, Hu LH, Wang YQ, Chen P, Huang JG,
Lu N, He JH and Liao CG: miR-22 is down-regulated in gastric
cancer, and its overexpression inhibits cell migration and invasion
via targeting transcription factor Sp1. Med Oncol. 30:5422013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: MiR-145, miR-133a and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang J, Lv X, Fan L, Huang G, Zhan Y,
Wang M and Lu H: MicroRNA-27b suppresses growth and invasion of
NSCLC cells by targeting Sp1. Tumour Biol. 35:10019–10023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang R, Luo H, Wang S, Chen W, Chen Z,
Wang HW, Chen Y, Yang J, Zhang X, Wu W, et al: MicroRNA-377
inhibited proliferation and invasion of human glioblastoma cells by
directly targeting specificity protein 1. Neuro Oncol.
16:1510–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Li M, Zang W, Ma Y, Wang N, Li P,
Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and
suppresses invasion by targeting Bcl-2 and SP-1 in esophageal
carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar
|
|
49
|
Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y,
Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility
by downregulating Sp1 in prostate cancer cells. Oncol Rep.
30:327–333. 2013.PubMed/NCBI
|
|
50
|
Cui F, Wang S, Lao I, Zhou C, Kong H,
Bayaxi N, Li J, Chen Q, Zhu T and Zhu H: miR-375 inhibits the
invasion and metastasis of colorectal cancer via targeting SP1 and
regulating EMT-associated genes. Oncol Rep. 36:487–493.
2016.PubMed/NCBI
|
|
51
|
Kang M, Xiao J, Wang J, Zhou P, Wei T,
Zhao T and Wang R: MiR-24 enhances radiosensitivity in
nasopharyngeal carcinoma by targeting SP1. Cancer Med. 5:1163–1173.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li X, Chen L, Wang W, Meng FB, Zhao RT and
Chen Y: MicroRNA-150 inhibits cell invasion and migration and is
downregulated in human osteosarcoma. Cytogenet Genome Res.
146:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
